Mr. Li’s company，It is a specialty engaged in medical research、Production、High -tech private pharmaceutical companies sold，Company successfully developed more than 30 national stake betting appstake online sports bettingnew drugs，On average, you can launch more than 10 new products per year。Enterprise terminal network spreads in most provinces in the country，and marketing institutions in major domestic cities，Nearly a thousand domestic target hospitals with large and medium -sized targets，Nearly 200 key commercial distribution units。
    For the company's current development，He seems very confident。"Some venture capital institutions called me，But I think the company's current development is very stable，We don’t need funds。"The answer of Mr. Li, the person in charge of this pharmaceutical company, is simply and resolute。
    At the same time，Another person in charge of another pharmaceutical company in Nanjing, which invested 300 million new drugs, also overturned the saying that it was intended to introduce venture capital。
    The reporter learned，52 listed companies in Nanjing，Only Nanjing Medicine、Three companies of Jinling Pharmaceutical stake betting appstake sports betting appStake Sports Bettingand Xianyou Pharmaceutical。Not long ago，China's largest biomedical outsourcing enterprise, one of the largest biomedical outsourcing companies, Kingste Technology (Nanjing) Co., Ltd.。"Now biomedicine focuses on the eyes of investors，Here is a new round of opportunities for wealth creation after the Internet。"The founding partner of the Kaipeng Huaying Venture Capital Fund, Zhong Xiaolin, previously said to the outside world。and Sequoia、SoftBank、Lenovo Investment and other institutions have previously said，Optimistic new medicine、Special medicines and patented Chinese medicine companies。Why do some pharmaceutical companies in Nanjing do not want to introduce venture capital? 
   "This depends on his conservative，If you are listed，His product、The company's plan must be made public，This is a question about transparency。"A large venture capital institution related person said。Yin Zhong, chief engineer of Nanjing Pharmaceutical stake betting appstake sports betting appstake betting appIndustry Group, believes，"China's pharmaceutical industry is unwilling to accept venture capital，Because the conditions for venture capital are too high，He is unacceptable for companies with no profit or less profitable enterprise。Of course，performance is also the main inspection aspect，But the growth period of the enterprise is the most difficult，This causes two aspects to be unable to talk about。There is also the environment in China、Under the background，This is difficult to succeed，China and the United States are different，Investment funds in the United States can drift water，But China can't do it at all，There is a special pharmaceutical industry funds in the United States，China No，There is no risk when mixed operations，China's venture capital company requires 30%of the company's profit before investing，But at present this is difficult。”